EUVIMEDEUVIMED entdecken
Systematische Übersicht

Blood-based biomarkers in hepatocellular carcinoma immunotherapy: a systematic review and prioritization for future validation

Yuliya V. Perfilyeva, Nurshat Abdolla, Aikyn Kali, Raikhan Tleulieva, Anastassiya V. Perfilyeva, Yekaterina O. Ostapchuk

Translational Gastroenterology and Hepatology · 2023-01 · 0-0

DOI: 10.21037/tgh-2026-0182 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Translational Gastroenterology and Hepatology, 2023-01. Verfasst von Yuliya V. Perfilyeva und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical outcomes following immune checkpoint inhibitor (ICI)-based therapy for hepatocellular carcinoma (HCC) remain highly variable. Reliable blood-based biomarkers are needed to improve patient stratification and guide treatment selection, yet the most promising candidates remain uncertain. This systematic review evaluated baseline circulating biomarkers associated with survival and treatment response and prioritized candidates for future validation.

Methods

A systematic literature search of PubMed, Web of Science, and Scopus was conducted through February 26, 2026. Eligible studies included cohorts of >30 adults with HCC receiving ICI-based therapy that evaluated baseline blood-based biomarkers in relation to survival outcomes. Study quality and risk of bias were assessed using the QUALSYST tool. A semi-quantitative prioritization framework integrating validation status, replication across separate studies, discriminatory performance, clinical applicability, and breadth of clinically relevant associations was developed to identify the most promising biomarkers.

Results

Fifty-nine studies comprising 12,008 patients met the inclusion criteria. Fifty-three baseline blood-based biomarkers were identified, including routine laboratory and inflammatory markers, soluble mediators and immune-related proteins, tumor-associated circulating biomarkers, immune cell-based biomarkers, and composite prognostic scores. Using the exploratory semi-quantitative prioritization framework, interleukin-6 (IL-6), magnesium, the systemic immune-inflammation index (SII), and the systemic inflammation response index (SIRI) received the highest cumulative scores among individual biomarkers and inflammatory indices. Additionally, the modified tumor marker (mTM) score, IL-6, and fibroblast growth factor 21 (FGF21) demonstrated potential predictive value across different ICI-based regimens. The evidence was limited by predominantly retrospective study designs, geographic concentration in Asia, and limited independent validation of most biomarkers.

Conclusions

Several baseline blood-based biomarkers have accumulated sufficient evidence to warrant prospective validation and may improve patient stratification and treatment selection. The review was registered in PROSPERO (CRD420261456784).

Zitieren

APA

Perfilyeva, Y. V., Abdolla, N., Kali, A., Tleulieva, R., Perfilyeva, A. V., & Ostapchuk, Y. O. (2023). Blood-based biomarkers in hepatocellular carcinoma immunotherapy: a systematic review and prioritization for future validation. Translational Gastroenterology and Hepatology, 0, 0-0. https://doi.org/10.21037/tgh-2026-0182

Vancouver

Perfilyeva YV, Abdolla N, Kali A, Tleulieva R, Perfilyeva AV, Ostapchuk YO. Blood-based biomarkers in hepatocellular carcinoma immunotherapy: a systematic review and prioritization for future validation. Translational Gastroenterology and Hepatology. 2023;0:0-0. doi:10.21037/tgh-2026-0182

BibTeX
@article{Perfilyeva2023,
  author = {Perfilyeva, Yuliya V. and Abdolla, Nurshat and Kali, Aikyn and Tleulieva, Raikhan and Perfilyeva, Anastassiya V. and Ostapchuk, Yekaterina O.},
  title = {Blood-based biomarkers in hepatocellular carcinoma immunotherapy: a systematic review and prioritization for future validation},
  journal = {Translational Gastroenterology and Hepatology},
  year = {2023},
  volume = {0},
  pages = {0--0},
  doi = {10.21037/tgh-2026-0182}
}
Kostenlos starten →